DE19821060A1 - Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung - Google Patents

Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Info

Publication number
DE19821060A1
DE19821060A1 DE19821060A DE19821060A DE19821060A1 DE 19821060 A1 DE19821060 A1 DE 19821060A1 DE 19821060 A DE19821060 A DE 19821060A DE 19821060 A DE19821060 A DE 19821060A DE 19821060 A1 DE19821060 A1 DE 19821060A1
Authority
DE
Germany
Prior art keywords
cells
polypeptide
molecule
antibody
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19821060A
Other languages
German (de)
English (en)
Inventor
Richard Prof Dr Kroczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Original Assignee
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7843330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19821060(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE19821060A priority Critical patent/DE19821060A1/de
Application filed by BUNDESREPUBLIK DEUTSCHLAND LET, Robert Koch Institute filed Critical BUNDESREPUBLIK DEUTSCHLAND LET
Priority to US09/509,283 priority patent/US7259247B1/en
Priority to AU13320/99A priority patent/AU752433B2/en
Priority to DE59813875T priority patent/DE59813875D1/de
Priority to ES98956800T priority patent/ES2279585T3/es
Priority to EP98956800A priority patent/EP1017723B1/de
Priority to JP2000512857A priority patent/JP4463418B2/ja
Priority to CA2305350A priority patent/CA2305350C/en
Priority to PCT/DE1998/002896 priority patent/WO1999015553A2/de
Publication of DE19821060A1 publication Critical patent/DE19821060A1/de
Priority to US09/823,307 priority patent/US7132099B2/en
Priority to US09/972,524 priority patent/US7125551B2/en
Priority to US10/647,072 priority patent/US7306800B2/en
Priority to US11/977,342 priority patent/US20090074784A1/en
Priority to US11/977,335 priority patent/US20080118513A1/en
Priority to US11/977,334 priority patent/US7722872B2/en
Priority to JP2009211970A priority patent/JP5021008B2/ja
Priority to US12/732,360 priority patent/US20120045447A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19821060A 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung Withdrawn DE19821060A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US09/509,283 US7259247B1 (en) 1997-09-23 1998-09-23 Anti-human T-cell costimulating polypeptide monoclonal antibodies
AU13320/99A AU752433B2 (en) 1997-09-23 1998-09-23 Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
DE59813875T DE59813875D1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
ES98956800T ES2279585T3 (es) 1997-09-23 1998-09-23 Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
EP98956800A EP1017723B1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
JP2000512857A JP4463418B2 (ja) 1997-09-23 1998-09-23 Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
CA2305350A CA2305350C (en) 1997-09-23 1998-09-23 Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
PCT/DE1998/002896 WO1999015553A2 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US09/823,307 US7132099B2 (en) 1997-09-23 2001-04-02 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US09/972,524 US7125551B2 (en) 1997-09-23 2001-10-04 Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
US10/647,072 US7306800B2 (en) 1997-09-23 2003-08-22 Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
US11/977,342 US20090074784A1 (en) 1997-09-23 2007-10-23 Treatment of chronic viral diseases with antibodies to costimulating polypeptide of T cells
US11/977,335 US20080118513A1 (en) 1997-09-23 2007-10-23 Treatment of immune disorders with antibodies to costimulating polypeptide of T cells
US11/977,334 US7722872B2 (en) 1997-09-23 2007-10-23 Treatment of cancer with antibodies to costimulating polypeptide of T cells
JP2009211970A JP5021008B2 (ja) 1997-09-23 2009-09-14 Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
US12/732,360 US20120045447A1 (en) 1997-09-23 2010-03-26 T cell costimulating polypeptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19741929 1997-09-23
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
DE19821060A1 true DE19821060A1 (de) 1999-04-15

Family

ID=7843330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19821060A Withdrawn DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Country Status (3)

Country Link
US (6) US7132099B2 (https=)
JP (1) JP5021008B2 (https=)
DE (1) DE19821060A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936035A1 (de) * 1999-07-30 2001-02-08 Univ Leipzig Lymphozytenproliferationstestkit
US6803039B2 (en) * 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305350C (en) * 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
KR20060129340A (ko) * 2003-12-30 2006-12-15 시그마-알드리치컴퍼니 효소 소화에 의한 핵산의 신속한 제조
EP1740617B1 (en) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
EP2482849B1 (en) * 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
ES2724451T3 (es) * 2010-02-04 2019-09-11 Univ Pennsylvania ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
AU4416189A (en) 1988-10-06 1990-05-01 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble t cell surface molecules
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247612B2 (en) 1997-02-27 2007-07-24 Japan Tobacco Inc. Methods of treating an inflammatory disease with a JJT-1 polypeptide
US7196175B2 (en) 1997-02-27 2007-03-27 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US8389690B2 (en) 1997-02-27 2013-03-05 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US7294473B2 (en) 1997-02-27 2007-11-13 Japan Tobacco Inc. Methods of identifying substances that interact with JTT-1 protein
US7932358B2 (en) 1997-02-27 2011-04-26 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7217792B2 (en) 1997-02-27 2007-05-15 Japan Tobacco Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US7279560B2 (en) 1997-02-27 2007-10-09 Japan Tobacco Inc. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
US7226909B2 (en) 1997-02-27 2007-06-05 Japan Tobacco Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7259147B2 (en) 1997-02-27 2007-08-21 Japan Tobacco Inc. Methods of treating multiple sclerosis with a JTT-1 polypeptide
DE19936035C2 (de) * 1999-07-30 2002-11-21 Univ Leipzig Lymphozytenproliferationstestkit
DE19936035A1 (de) * 1999-07-30 2001-02-08 Univ Leipzig Lymphozytenproliferationstestkit
US7998478B2 (en) 1999-08-30 2011-08-16 Japan Tobacco, Inc. Pharmaceutical composition for treating immune diseases
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
US7166283B2 (en) 2000-05-18 2007-01-23 Japan Tobacco Inc. Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
US7988965B2 (en) 2000-05-18 2011-08-02 Japan Tobacco, Inc. Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim
US6803039B2 (en) * 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US8052972B2 (en) 2001-03-27 2011-11-08 Japan Tobacco, Inc. Remedies for inflammatory bowel diseases

Also Published As

Publication number Publication date
US20020177191A1 (en) 2002-11-28
US7125551B2 (en) 2006-10-24
US7306800B2 (en) 2007-12-11
US7132099B2 (en) 2006-11-07
US7722872B2 (en) 2010-05-25
JP5021008B2 (ja) 2012-09-05
US20120045447A1 (en) 2012-02-23
US20090074784A1 (en) 2009-03-19
US20050261489A1 (en) 2005-11-24
US20020182667A1 (en) 2002-12-05
JP2010042007A (ja) 2010-02-25
US20080286283A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
EP1017723B1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE19821060A1 (de) Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE69333591T2 (de) CD40CR-Rezeptor und Liganden dafür
DE69535375T2 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69132306T2 (de) Menschlicher und Murin-Interleukin-5-Rezeptor
DE68928915T2 (de) Immunotherapie mit einbeziehung der cd28-stimulation
DE60217839T2 (de) Mittel zur suppression von transplantat-abstossung
DE69233482T2 (de) Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69333038T2 (de) Chimäre rezeptorgene und entsprechend damit transformierte zellen
DE3856301T2 (de) Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten-funktion assoziierten antigens-3
DE69000338T2 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE69738138T2 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
DE69331175T2 (de) Interleukin-2 Rezeptor Gamma-Kette
DE69320336T2 (de) Isolierung, Charakterisierung und Verwendung der menschlichen Beta-Einheit des Immunglobulin E-Hochaffinitätsrezeptors
EP1600460A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
DE69820449T2 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
DE69734141T2 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
DE69736109T2 (de) Differenzierungsinhibitor
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
DE69028713T3 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE69931776T2 (de) Verfahren zur klonierung von genen
DE69623746T2 (de) Icam-4 material und verfahren
DE69434731T2 (de) Ein Gen das für ein Polypeptid kodiert welches die Fähigkeit hat Prä-B Zellwachstum zu ermöglichen
DE69929876T2 (de) Für hm1.24 antigen kodierendes gen und dessen promotor

Legal Events

Date Code Title Description
8141 Disposal/no request for examination